Optimizing compliance with latent tuberculosis infection screening among kidney transplant recipients
Revista Española de Quimioterapia · 2025
DOI: 10.37201/req/002.2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Española de Quimioterapia, 2025. Verfasst von Alfonso Gotor-Rivera und 13 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Dermatología, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Esp…. Hauptthemen laut MEDLINE: Latent Tuberculosis, Kidney Transplantation, Mass Screening, Transplant Recipients. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
The increased risk of tuberculosis (TB) reactivation in solid organ transplant recipients supports the recommendation of screening for latent tuberculosis infection (LTBI). Adherence to available screening tests has not been studied in the kidney transplant (KT) population. We aimed to assess screening compliance within the ATALANTA-DOS population study.
Methods
ATALANTA-DOS studied an intervention bundle aimed at preventing infection in KT recipients. We compared LTBI screening rates between the pre-intervention (February 2016 – September 2017) and intervention (February 2018 – September 2019) cohorts and evaluated adherence rates between the interferon-gamma release assay (IGRA) and the tuberculin skin test (TST).
Results
A total of 307 KT recipients were included (155 in the pre-intervention cohort; 148 in the intervention cohort). A systematic assessment of screening compliance by an infectious disease specialist on day +30 post-KT improved LTBI screening adherence (82.6% [114/138] vs 1.3% [2/155]; p-value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Servicio de Dermatología, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, España. alfonso.gotor@salud.madrid.org.
- Unidad de Enfermedades Infecciosas, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, España.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, España.
- Departamento de Medicina, Universidad Complutense de Madrid, Madrid, España.
- Servicio de Nefrología, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, España.
ORCID-Profile: Alfonso Gotor-Rivera, Lucia de Jorge-Huerta, Isabel Rodríguez-Goncer, María Asunción Pérez-Jacoiste Asín, Tamara Ruiz-Merlo, Carlos Heredia-Mena, Rafael San-Juan, Amado Andrés, José María Aguado
Zitieren
APA
Gotor-Rivera, A., de Jorge-Huerta, L., Silva, J. T., Fernández-Ruiz, M., Rodríguez-Goncer, I., Pérez-Jacoiste Asín, M. A., Ruiz-Merlo, T., Heredia-Mena, C., González-Monte, E., Polanco, N., San-Juan, R., Andrés, A., Aguado, J. M., & López-Medrano, F. (2025). Optimizing compliance with latent tuberculosis infection screening among kidney transplant recipients. Revista Española de Quimioterapia. https://doi.org/10.37201/req/002.2025
Vancouver
Gotor-Rivera A, de Jorge-Huerta L, Silva JT, Fernández-Ruiz M, Rodríguez-Goncer I, Pérez-Jacoiste Asín MA, et al. Optimizing compliance with latent tuberculosis infection screening among kidney transplant recipients. Revista Española de Quimioterapia. 2025. doi:10.37201/req/002.2025
BibTeX
@article{GotorRivera2025,
author = {Gotor-Rivera, Alfonso and de Jorge-Huerta, Lucia and Silva, José Tiago and Fernández-Ruiz, Mario and Rodríguez-Goncer, Isabel and Pérez-Jacoiste Asín, María Asunción and Ruiz-Merlo, Tamara and Heredia-Mena, Carlos and González-Monte, Esther and Polanco, Natalia and San-Juan, Rafael and Andrés, Amado and Aguado, José María and López-Medrano, Francisco},
title = {Optimizing compliance with latent tuberculosis infection screening among kidney transplant recipients},
journal = {Revista Española de Quimioterapia},
year = {2025},
doi = {10.37201/req/002.2025}
}
EUVIMED